<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK1180" /><meta name="ncbi_domain" content="gene" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK1180/" /><meta name="ncbi_pagename" content="Familial Dysautonomia - GeneReviews® - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>Familial Dysautonomia - GeneReviews® - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.14.8/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.14.8/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="GeneReviews® [Internet]" /><meta name="citation_title" content="Familial Dysautonomia" /><meta name="citation_publisher" content="University of Washington, Seattle" /><meta name="citation_date" content="2014/12/18" /><meta name="citation_author" content="Mordechai Shohat" /><meta name="citation_author" content="Monika Weisz Hubshman" /><meta name="citation_pmid" content="20301359" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK1180/" /><meta name="citation_keywords" content="Hereditary Sensory and Autonomic Neuropathy, Type III (HSAN III)" /><meta name="citation_keywords" content="Riley-Day Syndrome" /><meta name="citation_keywords" content="Riley-Day Syndrome" /><meta name="citation_keywords" content="Hereditary Sensory and Autonomic Neuropathy, Type III (HSAN III)" /><meta name="citation_keywords" content="Elongator complex protein 1" /><meta name="citation_keywords" content="ELP1" /><meta name="citation_keywords" content="Familial Dysautonomia" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Familial Dysautonomia" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="University of Washington, Seattle" /><meta name="DC.Contributor" content="Mordechai Shohat" /><meta name="DC.Contributor" content="Monika Weisz Hubshman" /><meta name="DC.Date" content="2014/12/18" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK1180/" /><meta name="description" content="Familial dysautonomia (FD) affects the development and survival of sensory, sympathetic, and parasympathetic neurons. It is a debilitating disease present from birth. Neuronal degeneration progresses throughout life. Affected individuals have gastrointestinal dysfunction, vomiting crises, recurrent pneumonia, altered sensitivity to pain and temperature perception, and cardiovascular instability. About 40% of individuals have autonomic crises. Hypotonia contributes to delay in acquisition of motor milestones. Older individuals often have a broad-based and ataxic gait that deteriorates over time. Life expectancy is decreased." /><meta name="og:title" content="Familial Dysautonomia" /><meta name="og:type" content="book" /><meta name="og:description" content="Familial dysautonomia (FD) affects the development and survival of sensory, sympathetic, and parasympathetic neurons. It is a debilitating disease present from birth. Neuronal degeneration progresses throughout life. Affected individuals have gastrointestinal dysfunction, vomiting crises, recurrent pneumonia, altered sensitivity to pain and temperature perception, and cardiovascular instability. About 40% of individuals have autonomic crises. Hypotonia contributes to delay in acquisition of motor milestones. Older individuals often have a broad-based and ataxic gait that deteriorates over time. Life expectancy is decreased." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK1180/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/gene/fd/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK1180/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE880F07E04166610000000001FB00C7.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sparcle">Sparcle</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All GeneReviews" href="/books/n/gene/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" alt="Cover of GeneReviews®" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>GeneReviews<sup>®</sup> [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK1180_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK1180_dtls__"><div>Adam MP, Ardinger HH, Pagon RA, et al., editors.</div><div>Seattle (WA): <a href="http://www.washington.edu" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">University of Washington, Seattle</a>; 1993-2019.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/gene/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search GeneReviews" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search GeneReviews" submit="false" style="padding: 0.1em 0.4em;" /></div></form><div><ul class="inline_list"><li><a href="/books/n/gene/advanced/">GeneReviews Advanced Search</a></li><li style="margin-left:.5em"><a href="/books/n/gene/helpadvsearch/">Help</a></li></ul></div></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/factor-v-leiden/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/fevr/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK1180_"><span class="title" itemprop="name">Familial Dysautonomia</span></h1><div itemprop="alternativeHeadline" class="subtitle whole_rhythm">Synonyms: Hereditary Sensory and Autonomic Neuropathy, Type III (HSAN III); Riley-Day Syndrome</div><p class="contrib-group"><span itemprop="author">Mordechai Shohat</span>, MD and <span itemprop="author">Monika Weisz Hubshman</span>, MD, PhD.</p><a data-jig="ncbitoggler" href="#__NBK1180_ai__" style="border:0;text-decoration:none">Author Information</a><div style="display:none" class="ui-widget" id="__NBK1180_ai__"><div class="contrib half_rhythm"><span itemprop="author">Mordechai Shohat</span>, MD<div class="affiliation small">Director, Maccabi Genetic Institute<br />Medical Genetics, Cancer Research Center<br />Sheba Medical Center at Tel HaShomer</div><div class="affiliation small">Head, Adler Chair for Pediatric Cardiology<br />Professor, Pediatrics and Genetics<br />Sackler School of Medicine<br />Tel Aviv, Israel<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="li.ca.uat.tsop@tahohsm" class="oemail">li.ca.uat.tsop@tahohsm</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Monika Weisz Hubshman</span>, MD, PhD<div class="affiliation small">Schneider Children&#x02019;s Medical Center of Israel<br />Molecular Genetics / Medical Genetics<br />The Raphael Recanati Genetic Institute<br />Rabin Medical Center, Beilinson Hospital<br />Petah Tikva, Israel<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="li.gro.tilalc@ewacinom" class="oemail">li.gro.tilalc@ewacinom</a></div></div></div></div><p class="small">Initial Posting: <span itemprop="datePublished">January 21, 2003</span>; Last Update: <span itemprop="dateModified">December 18, 2014</span>.</p><p><em>Estimated reading time: 27 minutes</em></p></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div id="fd.Summary" itemprop="description"><h2 id="_fd_Summary_">Summary</h2><div><h4 class="inline">Clinical characteristics.</h4><p>Familial dysautonomia (FD) affects the development and survival of sensory, sympathetic, and parasympathetic neurons. It is a debilitating disease present from birth. Neuronal degeneration progresses throughout life. Affected individuals have gastrointestinal dysfunction, vomiting crises, recurrent pneumonia, altered sensitivity to pain and temperature perception, and cardiovascular instability. About 40% of individuals have autonomic crises. Hypotonia contributes to delay in acquisition of motor milestones. Older individuals often have a broad-based and ataxic gait that deteriorates over time. Life expectancy is decreased.</p></div><div><h4 class="inline">Diagnosis/testing.</h4><p>The diagnosis of FD is established by <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> of <i>ELP1</i> (<i>IKBKAP</i>). Two pathogenic variants account for more than 99% of mutated alleles in individuals with FD of <a class="def" href="/books/n/gene/glossary/def-item/ashkenazi-jewish/">Ashkenazi Jewish</a> descent. The major <a class="def" href="/books/n/gene/glossary/def-item/founder-variant/">founder variant</a> c.2204+6T&#x0003e;C (formerly IVS20+6T&#x0003e;C) is responsible for virtually all occurrences of FD among the Ashkenazim.</p></div><div><h4 class="inline">Management.</h4><p><i>Treatment of manifestations</i>: Maintenance of adequate nutrition; measures to avoid aspiration; standard treatment of gastroesophageal reflux (i.e., intravenous or rectal diazepam, rectal chloral hydrate, IV fluids for vomiting crises); daily chest physiotherapy; possible high-frequency chest-wall oscillation; hydration, elastic stockings, leg exercises, counter-maneuvers (e.g., squatting, bending forward, abdominal compression) to treat orthostatic hypotension; pacemaker for bradyarrhythmia and/or syncope; artificial tear solutions for corneal healing; spinal fusion as needed.</p><p><i>Prevention of secondary complications</i>: Adequate hydration during general anesthesia; attention to pressure points when fitting orthopedic devices; exercise to correct/prevent secondary contractures.</p><p><i>Surveillance</i>: Annual spine examination for scoliosis.</p></div><div><h4 class="inline">Genetic counseling.</h4><p>Familial dysautonomia is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> manner. At conception, each sib of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual has a 25% chance of being affected, a 50% chance of being an asymptomatic <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>, and a 25% chance of being unaffected and not a carrier. Once an at-risk sib is known to be unaffected, the chance of his/her being a carrier is 2/3. Carrier testing and <a class="def" href="/books/n/gene/glossary/def-item/prenatal-diagnosis/">prenatal diagnosis</a> for pregnancies at increased risk are possible if the pathogenic variants in the family are known.</p></div></div><div id="fd.Diagnosis"><h2 id="_fd_Diagnosis_">Diagnosis</h2><div id="fd.Suggestive_Findings"><h3>Suggestive Findings</h3><p>Prior to the introduction of clinical <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a>:</p><ul><li class="half_rhythm"><div class="half_rhythm">The diagnosis of <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> dysautonomia (FD) relied on the clinical recognition of both sensory and autonomic dysfunction and the presence of at least one parent of <a class="def" href="/books/n/gene/glossary/def-item/ashkenazi-jewish/">Ashkenazi Jewish</a> ancestry.</div><div class="half_rhythm">Note: (1) Some non-Jewish individuals reported to have FD have hereditary sensory and autonomic neuropathies (HSANs) other than FD. (2) At least one non-Jewish individual has had molecularly confirmed FD [<a class="bk_pop" href="#fd.REF.leyne.2003.305">Leyne et al 2003</a>].</div></li><li class="half_rhythm"><div class="half_rhythm">It was necessary for the following six cardinal features to be present in each <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual.</div></li></ul><p>With the specificity and wide availability of <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a>, the following are now considered suggestive findings on clinical evaluation and specialized testing.</p><p><b>Clinical findings</b></p><ul><li class="half_rhythm"><div>Hypotonia in infancy</div></li><li class="half_rhythm"><div>Decreased or absent deep tendon reflexes</div></li><li class="half_rhythm"><div>Decreased taste and absence of fungiform papillae of the tongue, giving it a smooth, pale appearance</div></li><li class="half_rhythm"><div>Absence of overflow tears with emotional crying (alacrima). Either history or the Schirmer test is used to establish this finding. As newborns do not cry tears, the Schirmer test must be performed after age six months. In the Schirmer test, the end of a filter paper, 5 mm wide and 35 mm long, is placed in the lateral portion of a lower eyelid. Less than 10 mm of wetting of the filter paper after five minutes indicates diminished baseline and reflex tear secretion.</div></li></ul><p><b>Specialized testing results</b></p><ul><li class="half_rhythm"><div>Absence of axon flare response after intradermal histamine injection</div></li><li class="half_rhythm"><div>Pupillary hypersensitivity to parasympathomimetic agents. Topical administration of methacholine 2.5% or pilocarpine 0.0625% has no observable effect on the normal pupil but causes miosis after approximately 20 minutes in almost all individuals with FD.</div></li></ul></div><div id="fd.Establishing_the_Diagnosis"><h3>Establishing the Diagnosis</h3><p>The diagnosis of <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> dysautonomia <b>is established</b> in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> pathogenic variants identified in <i>ELP1</i> (<i>IKBKAP</i>) on <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> (see <a class="figpopup" href="/books/NBK1180/table/fd.T.molecular_genetic_testing_used_in_f/?report=objectonly" target="object" rid-figpopup="figfdTmoleculargenetictestingusedinf" rid-ob="figobfdTmoleculargenetictestingusedinf">Table 1</a>).</p><p>Approaches to <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> include the following:</p><ul><li class="half_rhythm"><div class="half_rhythm">Targeted analysis for the two pathogenic variants that account for more than 99% of pathogenic variants in individuals with FD of <a class="def" href="/books/n/gene/glossary/def-item/ashkenazi-jewish/">Ashkenazi Jewish</a> descent [<a class="bk_pop" href="#fd.REF.dong.2002.253">Dong et al 2002</a>]. The major <a class="def" href="/books/n/gene/glossary/def-item/founder-variant/">founder variant</a> <a class="figpopup" href="/books/NBK1180/table/fd.T.selected_elp1_ikbkap_pathogenic_var/?report=objectonly" target="object" rid-figpopup="figfdTselectedelp1ikbkappathogenicvar" rid-ob="figobfdTselectedelp1ikbkappathogenicvar">c.2204+6T&#x0003e;C</a>, formerly IVS20+6T&#x0003e;C, is responsible for virtually all occurrences of FD among the Ashkenazim. The <a class="figpopup" href="/books/NBK1180/table/fd.T.selected_elp1_ikbkap_pathogenic_var/?report=objectonly" target="object" rid-figpopup="figfdTselectedelp1ikbkappathogenicvar" rid-ob="figobfdTselectedelp1ikbkappathogenicvar">p.Arg696Pro</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is rarely identified.</div></li><li class="half_rhythm"><div class="half_rhythm">Sequence analysis of the entire <a class="def" href="/books/n/gene/glossary/def-item/coding-region/">coding region</a> which identifies the two common pathogenic variants as well as rare variants, such as a proline-to-leucine pathogenic <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variant in <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 26, <a class="figpopup" href="/books/NBK1180/table/fd.T.selected_elp1_ikbkap_pathogenic_var/?report=objectonly" target="object" rid-figpopup="figfdTselectedelp1ikbkappathogenicvar" rid-ob="figobfdTselectedelp1ikbkappathogenicvar">p.Pro914Leu</a>, which was identified in an individual with FD who is not of <a class="def" href="/books/n/gene/glossary/def-item/ashkenazi-jewish/">Ashkenazi Jewish</a> heritage [<a class="bk_pop" href="#fd.REF.leyne.2003.305">Leyne et al 2003</a>]. If only one <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is identified and the clinical findings are suggestive, <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> should be considered.</div></li><li class="half_rhythm"><div class="half_rhythm">Use of a <a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a> that includes <i>ELP1</i> and other genes of interest (see <a href="#fd.Differential_Diagnosis">Differential Diagnosis</a>). Note: (1) The genes included in the panel and the diagnostic <a class="def" href="/books/n/gene/glossary/def-item/sensitivity/">sensitivity</a> of the testing used for each <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> vary by laboratory and are likely to change over time. (2) Some multigene panels may include genes not associated with the condition discussed in this <i>GeneReview</i>; thus, clinicians need to determine which multigene panel is most likely to identify the genetic cause of the condition at the most reasonable cost while limiting identification of variants of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a> and pathogenic variants in genes that do not explain the underlying <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>. (3) In some laboratories, panel options may include a custom laboratory-designed panel and/or custom phenotype-focused <a class="def" href="/books/n/gene/glossary/def-item/exome/">exome</a> analysis that includes genes specified by the clinician. (4) Methods used in a panel may include <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a>, <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>, and/or other non-sequencing-based tests.</div><div class="half_rhythm">For an introduction to multigene panels click <a href="/books/n/gene/app5/#app5.Multigene_Panels">here</a>. More detailed information for clinicians ordering genetic tests can be found <a href="/books/n/gene/app5/#app5.Multigene_Panels_FAQs">here</a>.</div></li></ul><div id="fd.T.molecular_genetic_testing_used_in_f" class="table"><h3><span class="label">Table 1. </span></h3><div class="caption"><p>Molecular Genetic Testing Used in Familial Dysautonomia</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1180/table/fd.T.molecular_genetic_testing_used_in_f/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__fd.T.molecular_genetic_testing_used_in_f_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_fd.T.molecular_genetic_testing_used_in_f_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene&#x000a0;<sup>1</sup></th><th id="hd_h_fd.T.molecular_genetic_testing_used_in_f_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Test Method</th><th id="hd_h_fd.T.molecular_genetic_testing_used_in_f_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Proportion of Probands with a Pathogenic Variant Detectable by This Method</th></tr></thead><tbody><tr><td headers="hd_h_fd.T.molecular_genetic_testing_used_in_f_1_1_1_1" rowspan="3" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><i>ELP1</i> (<i>IKBKAP</i>)</td><td headers="hd_h_fd.T.molecular_genetic_testing_used_in_f_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Targeted analysis for pathogenic variants&#x000a0;<sup>2</sup></td><td headers="hd_h_fd.T.molecular_genetic_testing_used_in_f_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x0003e;99% (<a class="def" href="/books/n/gene/glossary/def-item/ashkenazi-jewish/">Ashkenazi Jewish</a> population)&#x000a0;<sup>3</sup></td></tr><tr><td headers="hd_h_fd.T.molecular_genetic_testing_used_in_f_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Sequence analysis&#x000a0;<sup>4</sup></td><td headers="hd_h_fd.T.molecular_genetic_testing_used_in_f_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Unknown</td></tr><tr><td headers="hd_h_fd.T.molecular_genetic_testing_used_in_f_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Deletion/<a class="def" href="/books/n/gene/glossary/def-item/duplication/">duplication</a> analysis&#x000a0;<sup>5</sup></td><td headers="hd_h_fd.T.molecular_genetic_testing_used_in_f_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Unknown</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="fd.TF.1.1"><p class="no_margin">See <a href="/books/NBK1180/#fd.molgen.TA">Table A. Genes and Databases</a> for <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> and protein name. See <a href="#fd.Molecular_Genetics">Molecular Genetics</a> for information on allelic variants detected in this <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>.</p></div></dd><dt>2. </dt><dd><div id="fd.TF.1.2"><p class="no_margin">For pathogenic variants c.2204+6T&#x0003e;C and/or p.Arg696Pro</p></div></dd><dt>3. </dt><dd><div id="fd.TF.1.3"><p class="no_margin"><a class="bk_pop" href="#fd.REF.dong.2002.253">Dong et al [2002]</a></p></div></dd><dt>4. </dt><dd><div id="fd.TF.1.4"><p class="no_margin">Sequence analysis detects variants that are benign, likely benign, of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a>, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, and <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants; typically, <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> deletions/duplications are not detected. For issues to consider in interpretation of <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> results, click <a href="/books/n/gene/app2/">here</a>.</p></div></dd><dt>5. </dt><dd><div id="fd.TF.1.5"><p class="no_margin">Testing that identifies <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> deletions/duplications not detectable by <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> of the coding and flanking <a class="def" href="/books/n/gene/glossary/def-item/intronic/">intronic</a> regions of <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> DNA. Included in the variety of methods that may be used are: <a class="def" href="/books/n/gene/glossary/def-item/quantitative-pcr/">quantitative PCR</a>, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and <a class="def" href="/books/n/gene/glossary/def-item/chromosomal-microarray/">chromosomal microarray</a> (CMA) that includes this gene/<a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> segment.</p></div></dd></dl></div></div></div></div></div><div id="fd.Clinical_Characteristics"><h2 id="_fd_Clinical_Characteristics_">Clinical Characteristics</h2><div id="fd.Clinical_Description"><h3>Clinical Description</h3><p>Familial dysautonomia (FD) affects the development and survival of sensory, sympathetic, and parasympathetic neurons. It is a debilitating disease that is present from birth. Progressive neuronal degeneration continues throughout life. Affected individuals have gastrointestinal dysfunction, vomiting crises, recurrent pneumonia, altered sensitivity to pain and temperature, and cardiovascular instability (<a class="figpopup" href="/books/NBK1180/table/fd.T.clinical_manifestations_of_familial/?report=objectonly" target="object" rid-figpopup="figfdTclinicalmanifestationsoffamilial" rid-ob="figobfdTclinicalmanifestationsoffamilial">Table 2</a>) [<a class="bk_pop" href="#fd.REF.axelrod.1996">Axelrod 1996</a>, <a class="bk_pop" href="#fd.REF.axelrod.1999">Axelrod 1999</a>, <a class="bk_pop" href="#fd.REF.axelrod.2002.i2">Axelrod 2002</a>].</p><p>Infants and young children have varying degrees of hypotonia, contributing to delay in motor milestones. Episodic somnolence has been reported [<a class="bk_pop" href="#fd.REF.casella.2005.273">Casella et al 2005</a>]. In older individuals, the gait is often broad-based and ataxic. Progressive deterioration in gait occurs over time. Individuals with FD have difficulty performing rapid movements and maintaining their balance while changing direction or turning.</p><p>Pain insensitivity may result in failure to recognize fractures or inadvertent trauma to joints.</p><p>FD has always been recognized as a potentially life-threatening disorder with a high mortality rate and is associated with a high incidence of sudden death. Causes of death are primarily pulmonary (26%) and unexplained (38%); the latter may result from unopposed vagal stimulation. Sepsis is also a significant cause of death (11%). <a class="bk_pop" href="#fd.REF.axelrod.2002.i2">Axelrod [2002]</a> showed that improved supportive treatment has extended survival and the probability of an individual with FD reaching age 20 years has now increased to 60%.</p><p>Renal function tends to deteriorate with advancing age, possibly secondary to renal hypoperfusion from recurrent dehydration, postural hypotension, or vasoconstriction from sympathetic supersensitivity during autonomic crises. Persons with FD are far more likely than the general population to develop end-stage renal disease (ESRD). <a class="bk_pop" href="#fd.REF.elkayam.2006.780">Elkayam et al [2006]</a> reported that of individuals with FD alive at age 25 years, 19% eventually required dialysis, as compared with the national average of approximately 0.1%. Almost all persons with FD who reach their fourth decade have a markedly decreased glomerular filtration rate. The absence of feeding gastrostomy tube placement early in life and a greater extent of orthostatic hypotension appear to be risk factors for ESRD [<a class="bk_pop" href="#fd.REF.elkayam.2006.780">Elkayam et al 2006</a>].</p><div id="fd.T.clinical_manifestations_of_familial" class="table"><h3><span class="label">Table 2: </span></h3><div class="caption"><p>Clinical Manifestations of Familial Dysautonomia</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1180/table/fd.T.clinical_manifestations_of_familial/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__fd.T.clinical_manifestations_of_familial_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_fd.T.clinical_manifestations_of_familial_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">System Involved</th><th id="hd_h_fd.T.clinical_manifestations_of_familial_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Clinical Manifestations</th></tr></thead><tbody><tr><td headers="hd_h_fd.T.clinical_manifestations_of_familial_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Sensory system</b></td><td headers="hd_h_fd.T.clinical_manifestations_of_familial_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Insensitivity to pain (sparing hands, soles of feet, neck, and genital areas)&#x000a0;<sup>1</sup></div></li><li class="half_rhythm"><div>Abnormal temperature appreciation on the trunk and lower extremities&#x000a0;<sup>1</sup></div></li><li class="half_rhythm"><div>Depressed patellar reflexes</div></li></ul>
</td></tr><tr><td headers="hd_h_fd.T.clinical_manifestations_of_familial_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Autonomic system</b></td><td headers="hd_h_fd.T.clinical_manifestations_of_familial_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Oropharyngeal incoordination (60% of neonates)</div></li><li class="half_rhythm"><div>Esophageal dysmotility, gastroesophageal reflux&#x000a0;<sup>1</sup></div></li><li class="half_rhythm"><div>Insensitivity to hypercapnea and hypoxia&#x000a0;<sup>2</sup></div></li><li class="half_rhythm"><div>Breath holding</div></li><li class="half_rhythm"><div>Orthostatic hypotension without compensatory tachycardia&#x000a0;<sup>1,&#x000a0;3</sup></div></li><li class="half_rhythm"><div>Supine hypertension&#x000a0;<sup>1</sup></div></li></ul>
</td></tr><tr><td headers="hd_h_fd.T.clinical_manifestations_of_familial_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Motor system</b></td><td headers="hd_h_fd.T.clinical_manifestations_of_familial_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Hypotonia</div></li><li class="half_rhythm"><div>Mild/moderate developmental delay</div></li><li class="half_rhythm"><div>Broad-based or mildly ataxic gait&#x000a0;<sup>1</sup></div></li><li class="half_rhythm"><div>Spinal curvature (95%, especially kyphosis)&#x000a0;<sup>1</sup></div></li></ul>
</td></tr><tr><td headers="hd_h_fd.T.clinical_manifestations_of_familial_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Cranial nerves</b></td><td headers="hd_h_fd.T.clinical_manifestations_of_familial_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Absence of overflow tears</div></li><li class="half_rhythm"><div>Depressed corneal reflexes</div></li><li class="half_rhythm"><div>Optic nerve atrophy&#x000a0;<sup>1</sup></div></li><li class="half_rhythm"><div>Strabismus</div></li><li class="half_rhythm"><div>Deficient taste, especially sweet</div></li><li class="half_rhythm"><div>Dysarthric, nasal speech</div></li></ul>
</td></tr><tr><td headers="hd_h_fd.T.clinical_manifestations_of_familial_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Intelligence/personality</b></td><td headers="hd_h_fd.T.clinical_manifestations_of_familial_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Usually normal intelligence (verbal skills better than motor)</div></li><li class="half_rhythm"><div>Concrete or literal thinking</div></li><li class="half_rhythm"><div>Skin picking (especially fingers and nose)</div></li><li class="half_rhythm"><div>Resistance to change (phobias)&#x000a0;<sup>1</sup></div></li></ul>
</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Adapted from <a class="bk_pop" href="#fd.REF.axelrod.1996">Axelrod [1996]</a></p></div></dd><dt>1. </dt><dd><div id="fd.TF.2.1"><p class="no_margin">Progressive neurologic abnormalities</p></div></dd><dt>2. </dt><dd><div id="fd.TF.2.2"><p class="no_margin"><a class="bk_pop" href="#fd.REF.bernardi.2003.141">Bernardi et al [2003]</a></p></div></dd><dt>3. </dt><dd><div id="fd.TF.2.3"><p class="no_margin"><a class="bk_pop" href="#fd.REF.brown.2003.163">Brown et al [2003]</a></p></div></dd></dl></div></div></div><p>Oropharyngeal incoordination is manifest as poor sucking or discoordinated swallowing. It often persists and predisposes to aspiration pneumonia.</p><p>Autonomic crises occur in about 40% of individuals and are characterized by the following [<a class="bk_pop" href="#fd.REF.axelrod.1996">Axelrod 1996</a>]:</p><ul><li class="half_rhythm"><div>Excessive sweating of the head and trunk</div></li><li class="half_rhythm"><div>Erythematous blotching of the face and trunk</div></li><li class="half_rhythm"><div>Mottling (cutis marmorata) of distal extremities</div></li><li class="half_rhythm"><div>Hypertension and tachycardia</div></li><li class="half_rhythm"><div>Nausea/vomiting</div></li><li class="half_rhythm"><div>Severe dysphagia/drooling</div></li><li class="half_rhythm"><div>Irritability</div></li><li class="half_rhythm"><div>Insomnia</div></li><li class="half_rhythm"><div>Worsening of muscle tone</div></li></ul><p>Clinical manifestations of orthostatic hypotension worsen with age and include light-headedness or dizzy spells. Urinary incontinence is common in adolescent and adult women [<a class="bk_pop" href="#fd.REF.saini.2003.209">Saini et al 2003</a>].</p><p>Sexual maturation is frequently delayed, but sexual development is normal in both sexes. Women with FD have delivered normal infants following uncomplicated pregnancies. Fertility in males has been reported; one male has fathered six children.</p><p>Using a questionnaire to evaluate the quality of life in persons with FD, <a class="bk_pop" href="#fd.REF.sands.2006.457">Sands et al [2006]</a> determined that FD imposed a greater physical than psychosocial burden on children, whereas young adults reported both mental and physical quality of life within the average range. Self-esteem was problematic and improved with age. Both age groups reported decreasing physical quality of life with age, with worsening general health that limited their role at school or work [<a class="bk_pop" href="#fd.REF.sands.2006.457">Sands et al 2006</a>].</p><div id="fd.Neuropathology"><h4>Neuropathology</h4><p><b>Sensory nervous system.</b> The dorsal root ganglia are progressively reduced in size and number with time. Loss of dorsal column myelinated axons occurs over time.</p><p>The transverse fascicular area of the sural nerve in <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals of all ages is decreased because of reduction in the number of nonmyelinated axons and small-diameter myelinated axons. These characteristic findings allow differentiation from other sensory neuropathies.</p><p><b>Sympathetic nervous system.</b> The number of neurons is decreased in sympathetic ganglia. Autonomic nerve terminals are absent in peripheral blood vessels.</p><p><b>Parasympathetic nervous system.</b> The size and number of parasympathetic ganglia are decreased, but not as consistently as in the sympathetic nervous system.</p></div></div><div id="fd.GenotypePhenotype_Correlations"><h3>Genotype-Phenotype Correlations</h3><p>None has been observed [<a class="bk_pop" href="#fd.REF.blumenfeld.1999.1110">Blumenfeld et al 1999</a>].</p><p>The <a class="figpopup" href="/books/NBK1180/table/fd.T.selected_elp1_ikbkap_pathogenic_var/?report=objectonly" target="object" rid-figpopup="figfdTselectedelp1ikbkappathogenicvar" rid-ob="figobfdTselectedelp1ikbkappathogenicvar">p.Arg696Pro</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is extremely rare in the <a class="def" href="/books/n/gene/glossary/def-item/ashkenazi-jewish/">Ashkenazi Jewish</a> population and has never been detected in a <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> state; therefore, the <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> associated with p.Arg696Pro homozygosity is unknown.</p></div><div id="fd.Prevalence"><h3>Prevalence</h3><p>The incidence of FD among the Ashkenazim is 1:3,700 live births, which corresponds to a <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> frequency of 1:36 [<a class="bk_pop" href="#fd.REF.slaugenhaupt.2001.598">Slaugenhaupt et al 2001</a>]. A study by <a class="bk_pop" href="#fd.REF.lehavi.2003.139">Lehavi et al [2003]</a> from Israel identified 34 carriers among 1100 individuals of full <a class="def" href="/books/n/gene/glossary/def-item/ashkenazi-jewish/">Ashkenazi Jewish</a> parentage (<a class="def" href="/books/n/gene/glossary/def-item/carrier-rate/">carrier rate</a> 1:32). Further analysis revealed different carrier frequencies among a subset of Polish Ashkenazi Jews: Among the 195 individuals of full Polish background, 11 carriers were detected (1:18), in contrast to only three out of the 298 of full non-Polish background (1:99).</p></div></div><div id="fd.Genetically_Related_Allelic_Disorders"><h2 id="_fd_Genetically_Related_Allelic_Disorders_">Genetically Related (Allelic) Disorders</h2><p>No phenotypes other than those discussed in this <i>GeneReview</i> are known to be associated with mutation of <i>ELP1</i> (<i>IKBKAP</i>).</p></div><div id="fd.Differential_Diagnosis"><h2 id="_fd_Differential_Diagnosis_">Differential Diagnosis</h2><p><b>Hereditary sensory and autonomic neuropathies (HSANs).</b> Familial dysautonomia (FD) belongs to the family of HSANs [<a class="bk_pop" href="#fd.REF.hilz.2002.i33">Hilz 2002</a>]. Five HSANs are recognized:</p><ul><li class="half_rhythm"><div><a href="/books/n/gene/hsn1/"><b>HSAN IA</b></a>
<b>(hereditary sensory neuropathy type IA [HSN1A])</b> is an axonal form of hereditary motor and sensory neuropathy distinguished by prominent early sensory loss and later positive sensory phenomena including dysesthesia and characteristic "lightning" or "shooting" pains. Loss of sensation can lead to painless injuries, which, if unrecognized, result in slow wound healing and subsequent osteomyelitis requiring distal amputations. HSN1A is often associated with progressive sensorineural deafness. Motor involvement is present in all advanced cases and can be severe. After age 20 years, the distal wasting and weakness may involve proximal muscles so that in later life a wheelchair may be required for mobility. Drenching sweating of the hands and feet is sometimes reported and occasionally pupillary abnormalities are observed; however, visceral signs of autonomic involvement are rare. HSN1A is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> manner. <i>SPTLC1</i> pathogenic variants are identified in about 90% of individuals with a positive family history and about 10% of <a class="def" href="/books/n/gene/glossary/def-item/simplex/">simplex</a> cases (i.e., a single occurrence in a family).</div></li><li class="half_rhythm"><div><a href="/books/n/gene/hsan2/"><b>HSAN II</b></a>
<b>(hereditary sensory and autonomic neuropathy type II [HSAN2])</b> is characterized by progressively reduced sensation to pain, temperature, and touch. Symptoms occur in infancy or early childhood. Affected individuals have acral anhidrosis; ulcers, paronychia, whitlows, or other trophic changes of the fingers and toes; and other autonomic dysfunction including tonic pupils, oromotor incoordination, constipation from gastrointestinal dysmotility, bladder dysfunction, intermittent fevers, impaired sensory perception, hypotonia, and apnea. The sensory deficit is predominantly distal with the lower limbs more severely <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> than the upper limbs. Over time sensory function becomes severely reduced. Unrecognized injuries can lead to infections, osteomyelitis, fractures, and spontaneous amputation of digits. Neuropathic arthropathy (Charcot joints) occurs. Except for decreased or absent tendon reflexes, general neurologic examination is normal. HSAN2, which includes HSAN2A, HSAN2B, and HSAN2C, is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> manner.</div></li><li class="half_rhythm"><div><b>HSAN III</b> is <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> dysautonomia, the disorder described in this <i>GeneReview</i>.</div></li><li class="half_rhythm"><div><a href="/books/n/gene/hsan4/"><b>HSAN IV</b></a>
<b>(<a class="def" href="/books/n/gene/glossary/def-item/congenital/">congenital</a> insensitivity to pain with anhidrosis [CIPA])</b> is characterized by impaired autonomic, sensory, and motor function. CIPA closely resembles FD. Anhidrosis predisposes to high fevers if not managed properly. Insensitivity to superficial and deep pain results in mutilation (e.g., of tongue and cheek), neuropathic joints, risk for unrecognized injuries (burns, fractures), and corneal ulceration. Intellectual disability occurs. CIPA results from the presence of two <i>NTRK1</i> pathogenic variants. Typically one <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is inherited from each parent (<a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> inheritance); however, in some instances both pathogenic variants are from one parent (<a class="def" href="/books/n/gene/glossary/def-item/uniparental-disomy/">uniparental disomy</a>).</div></li><li class="half_rhythm"><div><b>HSAN V</b> (OMIM <a href="http://omim.org/entry/608654" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">608654</a>) is characterized by selective loss of pain perception but normal response to tactile, vibratory, and thermal stimuli. Neurologic examination is otherwise normal. HSAN V is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> manner and is caused by mutation of <i>NGF</i>.</div></li><li class="half_rhythm"><div><b>HSAN VI</b> (OMIM <a href="http://omim.org/entry/614653" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">614653</a>) is a lethal autonomic sensory neuropathy characterized by severe neonatal hypotonia, contractures, respiratory and feeding difficulties, and lack of psychomotor development. Autonomic abnormalities include labile cardiovascular function, lack of corneal reflexes leading to corneal scarring, areflexia, and absent axonal flare response after intradermal histamine injection. Homozygous pathogenic variants in <i>DST</i> (the <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> encoding dystonin) were described in an <a class="def" href="/books/n/gene/glossary/def-item/ashkenazi-jewish/">Ashkenazi Jewish</a> family [<a class="bk_pop" href="#fd.REF.edvardson.2012.569">Edvardson et al 2012</a>]. Inheritance is <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a>.</div></li><li class="half_rhythm"><div><b>HSAN VII</b> (OMIM <a href="http://omim.org/entry/615548" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">615548</a>) is caused by <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> pathogenic variants in <i>SCN11A</i>. Clinical characteristics include <a class="def" href="/books/n/gene/glossary/def-item/congenital/">congenital</a> insensitivity to pain leading to self-injuries, mild muscle weakness with delayed motor development, and normal cognitive function. Gastrointestinal dysfunction is also common. Inheritance is <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a>.</div></li></ul><p>See <a href="http://omim.org/phenotypicSeries/PS162400" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Hereditary sensory and autonomic neuropathy: OMIM Phenotypic Series</a> to view genes associated with this <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> in OMIM.</p><p><b>St&#x000fc;ve-Wiedemann syndrome</b> (OMIM <a href="http://omim.org/entry/601559" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">601559</a>) is associated with a combination of autonomic nervous system symptoms resembling FD and characteristic bony changes (bowing of long bones, camptodactyly) [<a class="bk_pop" href="#fd.REF.di_rocco.2003.362">Di Rocco et al 2003</a>]. St&#x000fc;ve-Wiedemann syndrome is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> manner and caused by mutation of <i>LIFR</i>.</p></div><div id="fd.Management"><h2 id="_fd_Management_">Management</h2><div id="fd.Evaluations_Following_Initial_Diagnos"><h3>Evaluations Following Initial Diagnosis</h3><p>To establish the extent of neurologic and intellectual impairment in an individual diagnosed with <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> dysautonomia, the following evaluations are recommended:</p><ul><li class="half_rhythm"><div>Standardized intelligence tests; frequently demonstrate better verbal than motor performance.</div></li><li class="half_rhythm"><div>Electroencephalography; may identify epileptic activity, although seizures with decerebrate posturing can follow breath holding even in children with normal EEG findings.</div></li><li class="half_rhythm"><div>Magnetic resonance imaging (MRI); frequently shows generalized atrophy, including in the cerebellum, which may contribute worsening of the ataxic gait and greater balance problems.</div></li><li class="half_rhythm"><div>Assessment of chronic respiratory disease including spirometry (possible from age 6 years onwards), arterial blood gases, polysomnography, and a swallow study</div></li><li class="half_rhythm"><div>Clinical genetics consultation</div></li></ul></div><div id="fd.Treatment_of_Manifestations"><h3>Treatment of Manifestations</h3><p><b>Feeding problems.</b> Maintain adequate nutrition and avoid aspiration. For infants, thickened formula and different-shaped nipples are useful in managing orophyaryngeal incoordination. Aversion to feeding and failure to thrive are managed frequently by percutaneous endoscopic gastrostomy (PEG) placement.</p><p><b>Gastroesophageal reflux.</b> Upright positioning with feeds, prokinetic agents, H2 antagonists, proton pump inhibitors, and gastrostomy with or without fundoplication are appropriate.</p><p><b>Vomiting crises</b> are treated with intravenous or rectal diazepam (0.2 mg/kg q3h) and rectal chloral hydrate (30 mg/kg q6h), and IV administration of fluids to prevent dehydration.</p><p>Other treatments used include [<a class="bk_pop" href="#fd.REF.palma.2014.2653">Palma et al 2014</a>]:</p><ul><li class="half_rhythm"><div>Alpha2 adrenergic agonist clonidine (transdermal clonidine patch): 0.1-0.3 mg/24h provides stable blood levels and is preferable to oral dosages. Clonidine, which augments baroreflex sensitivity and parasympathetic modulation in <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> dysautonomia, stabilizes the cardiovascular system and may attenuate feeding-induced crises [<a class="bk_pop" href="#fd.REF.marthol.2003.912">Marthol et al 2003</a>]. Although no controlled trials have been conducted, clonidine is frequently used in autonomic crisis. Slow tapering is recommended when discontinuing clonidine treatment [<a class="bk_pop" href="#fd.REF.palma.2014.2653">Palma et al 2014</a>].</div></li><li class="half_rhythm"><div>In some patients admitted to an ICU, dexmedetomidine (a selective agonist of alpha2 adrenoreceptors in the brain and spinal cord that inhibit sympathetic outflow) was effective.</div></li></ul><p>Carbidopa (a reversible dopa-decarboxylase inhibitor) 200 mg three times daily was assessed in a recent double-blind, randomized, placebo-controlled clinical trial that provided level II-b evidence that treatment with carbidopa can reduce the frequency and severity of hypertensive vomiting [<a class="bk_pop" href="#fd.REF.norcliffekaufmann.2013.1611">Norcliffe-Kaufmann et al 2013</a>].</p><p><b>Lung disease.</b> Chronic lung disease is treated with daily chest physiotherapy (nebulization, bronchodilators, cough augmentation, incentive spirometry, and postural drainage). <a class="bk_pop" href="#fd.REF.giarraffa.2005.3377">Giarraffa et al [2005]</a> determined that the use of high-frequency chest-wall oscillation improved all measured health outcomes significantly, including pneumonias, hospitalizations, antibiotic courses, antibiotic days, doctor visits, absenteeism, and oxygen saturation.</p><p>Early diagnosis of pneumonia and infectious agents is important due to the common involvement of gastric flora (secondary to aspirations).</p><p>Individuals with FD are prone to viral respiratory infections and, in some cases, concomitant bacterial infections. Treatment with oseltamivir is indicated for influenza virus infections [<a class="bk_pop" href="#fd.REF.palma.2014.2653">Palma et al 2014</a>].</p><p><b>Orthostatic hypotension.</b> Therapeutic measures include hydration, elastic stockings, and leg exercises to increase muscle tone and reduce pooling of blood in the veins of the legs.</p><p>Counter-maneuvers (e.g., squatting, bending forward, and abdominal compression) improve orthostatic blood pressure in persons with FD mainly by increasing cardiac output [<a class="bk_pop" href="#fd.REF.tutaj.2006.65">Tutaj et al 2006</a>]. Squatting had the greatest effect. However, the suitability and effectiveness of a specific counter-maneuver depend on the orthopedic and/or neurologic complications identified in each individual.</p><p>To determine whether fludrocortisone is effective in treating postural hypotension and whether it has an effect on survival and secondary long-term FD problems, <a class="bk_pop" href="#fd.REF.axelrod.2005.284">Axelrod et al [2005]</a> compared persons treated with fludrocortisone with untreated persons and found that cumulative survival was significantly higher during the first decade in treated versus untreated individuals. In subsequent decades, the addition of midodrine improved cumulative survival. Of note, treatment of orthostatic hypotension with high doses of fludrocortisone (&#x0003e;0.2 mg/day) was shown to accelerate the progression of renal damage in persons with FD [<a class="bk_pop" href="#fd.REF.norcliffekaufmann.2013.1611">Norcliffe-Kaufmann et al 2013</a>].</p><p><b>Hypertension.</b> Attention to factors precipitating hypertension rather than use of antihypertensive agents is appropriate because blood pressure is labile.</p><p>Sleeping with the head of the bed raised (20&#x000b0;-40&#x000b0;) helps to reduce orthostatic hypotension by lowering supine hypertension, reducing nocturnal pressure-diuresis, and raising intravascular volume in the morning.</p><p>The guidelines for hypertension treatment in patients with FD and chronic kidney disease are the same as for the general population.</p><p><b>Kidney and bladder.</b> Chronic renal failure, resulting from ischemic glomerulosclerosis, is common.</p><p>Adequate control of blood pressure is an important factor in delaying the appearance of kidney disease.</p><p>Renal tubular acidosis, which occurs frequently in FD, often requires treatment with bicarbonate.</p><p>Hyperkalemia, which is also common, is treated with low potassium diet.</p><p><b>Bradyarrhythmia.</b> Speculating that fatal bradyarrhythmia is an etiologic factor in sudden death associated with FD, <a class="bk_pop" href="#fd.REF.goldvon_simson.2005.15">Gold-von Simson et al [2005]</a> studied 20 persons with FD with a history of syncope and cardiac arrest and concluded that a pacemaker may protect from fatal bradyarrhythmia and may decrease the incidence of syncope.</p><p>If sleep-disordered breathing is confirmed, treatment with continuous positive airway pressure (CPAP) or bi-level positive airway pressure (BiPAP) must be initiated.</p><p><b>Eyes.</b> Decreased corneal sensation and absence of tearing predispose to corneal ulcerations, which can be managed with artificial tear solutions containing methylcellulose administered three to six times daily, maintenance of normal body hydration, and moisture chamber spectacle attachments. Soft contact lenses can promote corneal healing. Tarsorrhaphy is reserved for treatment of corneal injury that is unresponsive to these measures. Corneal transplantation has had limited success.</p><p>Chronic blepharitis is common and requires treatment with combined topical antibiotic/corticosteroid ointment.</p><p>Strabismus is almost always present (93%), and early surgical correction may help.</p><p><b>Spine.</b> Spinal fusion may be necessary.</p><p><b>Other</b></p><ul><li class="half_rhythm"><div>Many adults use walkers or wheelchairs when outside the home.</div></li><li class="half_rhythm"><div>Sialorrhea is a common. Surgical and anti-cholinergic drugs were used in the past. Recently the use of botulinium toxin injected to major salivary glands has been suggested [<a class="bk_pop" href="#fd.REF.daniel.2014.867">Daniel &#x00026; Cardona 2014</a>].</div></li></ul></div><div id="fd.Prevention_of_Secondary_Complications"><h3>Prevention of Secondary Complications</h3><p>Use of general anesthetics requires adequate hydration.</p><p>Fitting of braces requires care as reduced sensitivity to pain may cause decubitus ulcers to develop at pressure points.</p><p>Exercise can help correct or prevent secondary contractures.</p></div><div id="fd.Surveillance"><h3>Surveillance</h3><p>The following are appropriate:</p><ul><li class="half_rhythm"><div>Routine assessment of growth in children</div></li><li class="half_rhythm"><div>Periodic evaluation of chronic respiratory disease: spirometry (possible from age 6 years onwards), arterial blood gases, polysomnography, and a swallow study. Follow-up frequency depends on findings.</div></li><li class="half_rhythm"><div>Regular monitoring of blood pressure and optimal management of blood pressure lability to help prevent some of the neurologic progression with age, which can be associated with compromised cerebral perfusion</div></li><li class="half_rhythm"><div>Routine monitoring of other cardiovascular problems that can worsen with age (e.g., a greater degree of postural hypotension, worsening of supine hypertension, development of ischemic glomerulosclerosis, and cardiac arrhythmias) [<a class="bk_pop" href="#fd.REF.axelrod.2007.39">Axelrod &#x00026; Gold-von Simson 2007</a>]</div></li><li class="half_rhythm"><div>Monitoring for adequate hydration by measurement of blood urea nitrogen levels</div></li><li class="half_rhythm"><div>Screening for sleep-disordered breathing with polysomnography</div></li><li class="half_rhythm"><div>Periodic eye examination for strabismus, corneal opacities, or abnormal eye movements</div></li><li class="half_rhythm"><div>Annual examination of the spine for early evidence of scoliosis to permit timely institution of bracing and exercise therapy</div></li><li class="half_rhythm"><div>Periodic assessment of psychomotor development and behavior in children</div></li></ul></div><div id="fd.AgentsCircumstances_to_Avoid"><h3>Agents/Circumstances to Avoid</h3><p>Symptoms tend to be worse in hot or humid weather; patients should try to avoid being outdoors in such conditions as much as possible.</p><p>Other situations that can exacerbate disease manifestations include a full bladder; frequent visits to the lavatory are recommended [<a class="bk_pop" href="#fd.REF.axelrod.2007.39">Axelrod &#x00026; Gold-von Simson 2007</a>].</p><p>Since long car rides, coming out of a movie theater, or fatigue can also worsen symptoms, such situations should be avoided to the extent that this is possible [<a class="bk_pop" href="#fd.REF.axelrod.2007.39">Axelrod &#x00026; Gold-von Simson 2007</a>].</p><p>Episodic hypertension can occur in response to emotional stress or visceral pain, and therefore patients should also try to avoid these [<a class="bk_pop" href="#fd.REF.axelrod.2007.39">Axelrod &#x00026; Gold-von Simson 2007</a>].</p><p>Environmental situations associated with hypobaric hypoxia (e.g., aircraft flight or ascent to high altitude) pose a potential risk to patients with daytime hypercapnia [<a class="bk_pop" href="#fd.REF.palma.2014.2653">Palma et al 2014</a>].</p></div><div id="fd.Evaluation_of_Relatives_at_Risk"><h3>Evaluation of Relatives at Risk</h3><p>See <a href="#fd.Related_Genetic_Counseling_Issues">Genetic Counseling</a> for issues related to testing of at-risk relatives for <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> purposes.</p></div><div id="fd.Pregnancy_Management"><h3>Pregnancy Management</h3><p>Pregnancies in women with FD are considered high risk because of abrupt changes in blood pressure.</p><p>High blood pressure secondary to FD is difficult to differentiate from toxemia or other causes of pregnancy-related high blood pressure.</p><p>Awareness of volume loss and low blood pressure is important because of the absence of reflex tachycardia to low blood pressure.</p><p>Visceral pain related to contractions during labor is perceived normally; therefor, analgesia should be provided. Epidural anesthesia is preferable due to blood pressure lability during general anesthesia or spinal block [<a class="bk_pop" href="#fd.REF.maayan.2000.679">Maayan et al 2000</a>].</p></div><div id="fd.Therapies_Under_Investigation"><h3>Therapies Under Investigation</h3><p><b>Kinetin.</b> FD results from an <a class="def" href="/books/n/gene/glossary/def-item/intron/">intron</a> 20 <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> that causes a unique pattern of tissue-specific <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> skipping. Accurate <a class="def" href="/books/n/gene/glossary/def-item/splicing/">splicing</a> of the mutated <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> is particularly inefficient in the nervous system. <a class="bk_pop" href="#fd.REF.slaugenhaupt.2004.429">Slaugenhaupt et al [2004]</a> showed that treatment with the plant cytokinin kinetin alters splicing of <i>ELP1</i> (<i>IKBKAP</i>) and significantly increases inclusion of exon 20 from the endogenous <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>. <a class="bk_pop" href="#fd.REF.hims.2007.149">Hims et al [2007]</a> demonstrated that treatment of FD lymphoblast cell lines with kinetin increases <i>ELP1</i> <a class="def" href="/books/n/gene/glossary/def-item/mrna/">mRNA</a> and elongator complex protein 1 (Elp1, also known as IKBKAP or IKAP) to normal levels and that <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> of a region at the end of <i>ELP1</i> exon 20 disrupts the ability of kinetin to improve exon inclusion.</p><p>In a later study, <a class="bk_pop" href="#fd.REF.goldvon_simson.2009.341">Gold-von Simson et al [2009]</a> investigated whether oral kinetin altered <i>ELP1</i> <a class="def" href="/books/n/gene/glossary/def-item/splicing/">splicing</a> in vivo. They administered kinetin to 29 healthy carriers of the major <i>ELP1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> associated with FD and monitored adverse effects, as well as kinetin and <i>ELP1</i> <a class="def" href="/books/n/gene/glossary/def-item/mrna/">mRNA</a> levels. After eight days they found that <i>ELP1</i> mRNA expression in leukocytes increased as kinetin levels increased and noted that these findings strongly suggest a therapeutic role for kinetin in FD.</p><p>In a study conducted by <a class="bk_pop" href="#fd.REF.axelrod.2011.480">Axelrod et al [2011]</a>, kinetin was administered to eight individuals with FD at a dose of 23.5 mg/kg/d for 28 days. An increase in wild type <i>ELP1</i> <a class="def" href="/books/n/gene/glossary/def-item/mrna/">mRNA</a> expression in leukocytes was noted after eight days in six of the eight; after 28 days, the mean increase compared with baseline was significant (p = 0.002). Long-term clinical trials are warranted.</p><p><b>Induced pluripotent stem cells (iPSCs).</b> The isolation of human iPSCs offers a novel strategy for modeling human disease. <a class="bk_pop" href="#fd.REF.lee.2009.402">Lee et al [2009]</a> derived patient-specific FD-iPSCs from three persons with <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> dysautonomia and performed directed differentiation into cells of all three germ layers including peripheral neurons. They exposed FD-iPSC-derived neural crest precursors to kinetin, which resulted in a dramatic reduction of the mutated <i>ELP1</i> splice form. In contrast, no significant improvements in <i>ELP1</i> <a class="def" href="/books/n/gene/glossary/def-item/splicing/">splicing</a> were observed after ECGC or tocotrienol exposure. The kinetin-mediated decrease in mutated <i>ELP1</i> was associated with an increase in normal <i>ELP1</i> levels and the ratio of normal:mutated transcript. No significant increase in normal <i>ELP1</i> transcript levels was observed after kinetin treatment of neural crest precursors derived from control iPSCs.</p><p>Although short-term (1-day or 5-day) kinetin treatment of FD-iPSC-derived neural crest precursors had considerable effects on <i>ELP1</i> <a class="def" href="/books/n/gene/glossary/def-item/splicing/">splicing</a>, it did not result in a significant increase in the expression of neurogenic markers or improve migration behavior. They next tested the effect of continuous (28-day) kinetin treatment of FD-iPSCs starting at the pluripotent stage one day before differentiation. Notably, continuous kinetin treatment induced a significant increase in the percentage of differentiating neurons and in the expression of key peripheral neuron markers such as <i>ASCL1</i> and <i>SCG10</i> at the neural crest precursor stage. No significant increase was observed in FD-iPSC neural crest precursor cell migration, suggesting incomplete restoration of disease <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>. The authors note that while future studies will be required to define the developmental windows of kinetin action in greater detail, these data indicate that long-term treatment beginning in the early stage may be particularly beneficial in persons with FD.</p><p>More recently <a class="bk_pop" href="#fd.REF.lee.2012.1244">Lee et al [2012]</a> performed large scale screening using FD-induced pluripotent stem cells to identify compounds that rescue IKBKAP expression. They screened 6,912 small-molecule compounds and characterized eight that rescued expression of IKBKAP. One of the compounds, SKF-86466, was found to induce IKBKAP transcription through modulation of intracellular cAMP levels and PKA-dependent CREB phosphorylation. SKF-86466 also rescued IKAP protein expression and the disease-specific loss of autonomic neuronal marker expression. SKF or other compounds including kinetin do not rescue the migratory defect of FD-iPSC derived neural crest cells. Because it is not clear whether any of the compounds will affect degenerative aspects of the disease such as the survival of postmitotic sensory or autonomic neurons, more pre-clinical studies are required.</p><p><b>Tocotrienols.</b>
<a class="bk_pop" href="#fd.REF.anderson.2005.150">Anderson &#x00026; Rubin [2005]</a> found that individuals with FD have reduced MAO A <a class="def" href="/books/n/gene/glossary/def-item/mrna/">mRNA</a> levels, and that FD-derived cells, stimulated with tocotrienols (members of the vitamin E family) or (-)-epigallocatechin gallate (EGCG, a major polyphenolic antioxidant present in green tea to produce increased levels of functional Elp1, expressed increased amounts of MAO A mRNA transcript and protein. They found that administration of tocotrienol to individuals with FD resulted in increased expression of both functional Elp1 and MAO A transcripts in peripheral blood cells and suggested that this demonstrates the value of therapeutic approaches designed to elevate cellular levels of functional Elp1 and MAO A.</p><p>Subsequently, <a class="bk_pop" href="#fd.REF.rubin.2008.837">Rubin et al [2008]</a> examined the impact of tocotrienols on the frequency of hypertensive crises and cardiac function. After three to four months of tocotrienol ingestion, 80% of the patients reported a significant (50%) decrease in the number of crises. In a smaller group of patients, most exhibited a post-exercise increase in heart rate and a decrease in the QT interval. Based on these findings, the authors hypothesized that tocotrienol therapy would improve the long-term clinical outlook and survival of patients with FD.</p><p>In a study by <a class="bk_pop" href="#fd.REF.anderson.2012.570">Anderson et al [2012]</a> the simultaneous exposure of FD-derived cells to genistein and epigallocatechin gallate (EGCG) resulted in the almost exclusive production of the <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a>-20-containing transcript and the production of wild type amounts of IKAP protein. The authors suggest clinical evaluation of combined administration of these commonly used nutraceuticals.</p><p><b>Pregabalin.</b>
<a class="bk_pop" href="#fd.REF.axelrod.2009.743">Axelrod &#x00026; Berlin [2009]</a> investigated the use of pregabalin, a 3-isobutyl derivative of GABA known to have anticonvulsant, antiepileptic, anxiolytic, and analgesic activities, in the treatment of nausea and dysautonomic crises. They treated a cohort of 15 patients with FD who experienced frequent dysautonomic crises with pregabalin and found that nausea and overt crises markedly decreased in 13 (87%). The overall assessments of benefit were extremely favorable, prompting the authors to suggest that pregabalin may be a potentially useful therapeutic agent in FD.</p><p><b>Phosphatidylserine (PS).</b> Another study performed by <a class="bk_pop" href="#fd.REF.keren.2010.e15884">Keren et al [2010]</a> showed that PS, a phospholipidic component of cell membranes and FDA-approved food supplement, elevates the levels of IKAP (ELP-1) in FD cell lines. While kinetin increases the levels of correctly spliced IKAP transcripts (thus altering the ratio between <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 20 inclusion and skipping), phosphatidylserine appears to increase levels of transcription without altering the ratio. PS treatment of FD cells elevated wild type IKAP <a class="def" href="/books/n/gene/glossary/def-item/mrna/">mRNA</a> and protein levels and resulted in a cell cycle distribution similar to that of the control cells. A significant number of genes up-regulated following PS treatment are also involved in DNA metabolic processes and in DNA repair mechanisms. On increases in cellular metabolism and synthesis of nucleotides, transcription by RNA polymerase II increases; thus, the increase in mRNA levels is not specific to IKAP.</p><p>Recently, <a class="bk_pop" href="#fd.REF.bochner.2013.2785">Bochner et al [2013]</a> showed an increase of IKBAKP <a class="def" href="/books/n/gene/glossary/def-item/mrna/">mRNA</a> and IKAP protein levels following PS administration in various tissues of FD humanized mice (<a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> humanized mouse strain carrying human <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 20 and its two flanking introns) without affecting exon 20 inclusion levels. The authors of the studies suggest PS as a potential therapeutic agent.</p><p><b>Digoxin.</b> The cardiac glycoside digoxin was shown by <a class="bk_pop" href="#fd.REF.liu.2013.3632">Liu et al [2013]</a> to alter and increase the production of the wild type, <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 20-containing, I <i>ELP1</i>-encoded transcript and the full-length I&#x003ba;B-kinase-complex-associated protein in FD-derived cells. The digoxin-mediated effect on <a class="def" href="/books/n/gene/glossary/def-item/splicing/">splicing</a> was SRSF3-binding site dependent; the site is located in the <a class="def" href="/books/n/gene/glossary/def-item/intron/">intron</a> 5' of the alternatively spliced exon and digoxin was shown to mediate its effect by suppressing the level of the SRSF3 protein. These experiments were conducted in cells transfected with an <i>ELP1</i> minigene construct bearing the IVS20+6T&#x0003e;C <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>. The author suggests further investigation of the possible use of digoxin as a therapeutic modality for FD.</p><p>Search <a href="https://clinicaltrials.gov/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ClinicalTrials.gov</a> in the US and <a href="http://www.ClinicalTrialsRegister.eu" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.ClinicalTrialsRegister.eu</a> in Europe for access to information on clinical studies for a wide range of diseases and conditions.</p></div></div><div id="fd.Genetic_Counseling"><h2 id="_fd_Genetic_Counseling_">Genetic Counseling</h2><p>
<i>Genetic counseling is the process of providing individuals and families with
information on the nature, inheritance, and implications of genetic disorders to help them
make informed medical and personal decisions. The following section deals with genetic
risk assessment and the use of family history and genetic testing to clarify genetic
status for family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with a genetics
professional</i>. &#x02014;ED.</p><div id="fd.Mode_of_Inheritance"><h3>Mode of Inheritance</h3><p>Familial dysautonomia (FD) is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> manner.</p></div><div id="fd.Risk_to_Family_Members"><h3>Risk to Family Members</h3><p><b>Parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>The parents of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> child are obligate heterozygotes (i.e., carriers of one <i>ELP1</i> [<i>IKBKAP</i>] <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>).</div></li><li class="half_rhythm"><div>Heterozygotes are asymptomatic.</div></li></ul><p><b>Sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>At conception, each sib of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual has a 25% chance of being affected, a 50% chance of being an asymptomatic <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>, and a 25% chance of being unaffected and not a carrier.</div></li><li class="half_rhythm"><div>Once an at-risk sib is known to be unaffected, the chance of his/her being a <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> is 2/3.</div></li></ul><p><b>Offspring of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>All offspring of an individual with FD inherit a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>ELP1</i> from their <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> parent.</div></li><li class="half_rhythm"><div>The risk that the <a class="def" href="/books/n/gene/glossary/def-item/ashkenazi-jewish/">Ashkenazi Jewish</a> reproductive partner of an individual with FD is <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for an <i>ELP1</i> disease-causing <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> is 1:32. Thus, the risk to the offspring of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual and an Ashkenazi Jewish partner of having FD is approximately 1.5%. It is appropriate to offer <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> of <i>ELP1</i> to the Ashkenazi Jewish partner and to evaluate the offspring of an individual with FD with molecular genetic testing of <i>ELP1</i>.</div></li><li class="half_rhythm"><div>The risk that a person of non-<a class="def" href="/books/n/gene/glossary/def-item/ashkenazi-jewish/">Ashkenazi Jewish</a> ancestry is a <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> of FD is less than 1:150. For offspring of an individual with FD and a non-Ashkenazi Jewish reproductive partner, the risk of having FD is less than 1:300.</div></li></ul><p><b>Other family members.</b> Each sib of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>'s parents is at a 50% risk of being a <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> of an <i>ELP1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</p></div><div id="fd.Carrier_Detection"><h3>Carrier Detection</h3><p>Carrier testing is possible if the <i>ELP1</i> pathogenic variants have been identified in the family.</p><p>Carrier testing is possible for the <a class="def" href="/books/n/gene/glossary/def-item/ashkenazi-jewish/">Ashkenazi Jewish</a> reproductive partners of known carriers.</p></div><div id="fd.Related_Genetic_Counseling_Issues"><h3>Related Genetic Counseling Issues</h3><p><b>Population screening.</b> Because of the increased <i>ELP1</i> mutation frequency in Ashkenazi Jews and the availability of <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> and <a class="def" href="/books/n/gene/glossary/def-item/prenatal-diagnosis/">prenatal diagnosis</a>, <a class="def" href="/books/n/gene/glossary/def-item/targeted-analysis-for-pathogenic-variants/">targeted analysis for pathogenic variants</a> in <i>ELP1</i> is often included in the panel of "<a class="def" href="/books/n/gene/glossary/def-item/ashkenazi-jewish/">Ashkenazi Jewish</a> pathogenic variants" offered to individuals interested in preconception or prenatal risk assessment modification. Through this type of screening, couples in which both partners are carriers can be made aware of their status and risks before having <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> children. Then, through genetic counseling and the option of prenatal testing, such families can, if they choose, bring to term only those pregnancies in which the fetus is unaffected [<a class="bk_pop" href="#fd.REF.acog_committee_on_genetics.2004.425">ACOG Committee on Genetics 2004</a>].</p><p><b>Family planning</b></p><ul><li class="half_rhythm"><div>The optimal time for determination of genetic risk, clarification of <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> status, and discussion of the availability of prenatal testing is before pregnancy.</div></li><li class="half_rhythm"><div>It is appropriate to offer <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> (including discussion of potential risks to offspring and reproductive options) to young adults who are <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>, are carriers, or are at risk of being carriers.</div></li></ul><p><b>DNA banking</b> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals.</p></div><div id="fd.Prenatal_Testing_and_Preimplantation"><h3>Prenatal Testing and Preimplantation Genetic Diagnosis</h3><p>Once the <i>ELP1</i> pathogenic variants have been identified in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member, prenatal testing for a pregnancy at increased risk and <a class="def" href="/books/n/gene/glossary/def-item/preimplantation-genetic-diagnosis/">preimplantation genetic diagnosis</a> for FD are possible.</p></div></div><div id="fd.Resources"><h2 id="_fd_Resources_">Resources</h2><p>
<i>GeneReviews staff has selected the following disease-specific and/or umbrella
support organizations and/or registries for the benefit of individuals with this disorder
and their families. GeneReviews is not responsible for the information provided by other
organizations. For information on selection criteria, click <a href="/books/n/gene/app4/">here</a>.</i></p><ul><li class="half_rhythm"><div><b>Autonomic Disorders Consortium</b></div><div><a href="https://www.rarediseasesnetwork.org/cms/autonomic" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Autonomic Disorders Consortium</a></div></li><li class="half_rhythm"><div><b>Dysautonomia Foundation, Inc.</b></div><div>315 West 39th Street</div><div>Suite 701</div><div>New York NY 10018</div><div><b>Phone:</b> 212-279-1066</div><div><b>Fax:</b> 212-279-2066</div><div><b>Email:</b> info@famdys.org</div><div><a href="http://www.familialdysautonomia.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.familialdysautonomia.org</a></div></li><li class="half_rhythm"><div><b>National Library of Medicine Genetics Home Reference</b></div><div><a href="http://ghr.nlm.nih.gov/condition=familialdysautonomia" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Familial dysautonomia</a></div></li><li class="half_rhythm"><div><b>Center for Jewish Genetics</b></div><div>Ben Gurion Way</div><div>30 South Wells Street</div><div>Chicago IL 60606</div><div><b>Phone:</b> 312-357-4718</div><div><b>Email:</b> jewishgeneticsctr@juf.org</div><div><a href="http://www.jewishgenetics.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.jewishgenetics.org</a></div></li></ul></div><div id="fd.Molecular_Genetics"><h2 id="_fd_Molecular_Genetics_">Molecular Genetics</h2><p><i>Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information. &#x02014;</i>ED.</p><div id="fd.molgen.TA" class="table"><h3><span class="label">Table A.</span></h3><div class="caption"><p>Familial Dysautonomia: Genes and Databases</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1180/table/fd.molgen.TA/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__fd.molgen.TA_lrgtbl__"><table class="no_bottom_margin"><tbody><tr><th id="hd_b_fd.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Gene</th><th id="hd_b_fd.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">Chromosome Locus</th><th id="hd_b_fd.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">Protein</th><th id="hd_b_fd.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Locus-Specific Databases</th><th id="hd_b_fd.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">HGMD</th><th id="hd_b_fd.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">ClinVar</th></tr><tr><td headers="hd_b_fd.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/8518" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>ELP1</i></a></td><td headers="hd_b_fd.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=8518" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">9q31<wbr style="display:inline-block"></wbr>​.3</a></td><td headers="hd_b_fd.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/O95163" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Elongator complex protein 1</a></td><td headers="hd_b_fd.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.molgen.ua.ac.be/CMTMutations/Mutations/Contexts.cfm?ID=14" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">IPN Mutations, IKBKAP</a><br /><a href="https://databases.lovd.nl/shared/genes/IKBKAP" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">IKBKAP homepage - Leiden Muscular Dystrophy pages</a></td><td headers="hd_b_fd.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=ELP1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ELP1</a></td><td headers="hd_b_fd.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=ELP1[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ELP1</a></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div id="fd.TFA.1"><p class="no_margin">Data are compiled from the following standard references: <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> from
<a href="http://www.genenames.org/index.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HGNC</a>;
<a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> from
<a href="http://www.omim.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">OMIM</a>;
protein from <a href="http://www.uniprot.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">UniProt</a>.
For a description of databases (Locus Specific, HGMD, ClinVar) to which links are provided, click
<a href="/books/n/gene/app1/">here</a>.</p></div></dd></dl></div></div></div><div id="fd.molgen.TB" class="table"><h3><span class="label">Table B.</span></h3><div class="caption"><p>OMIM Entries for Familial Dysautonomia (<a href="/omim/223900,603722" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">View All in OMIM</a>) </p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1180/table/fd.molgen.TB/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__fd.molgen.TB_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/223900" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">223900</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NEUROPATHY, HEREDITARY SENSORY AND AUTONOMIC, TYPE III; HSAN3</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/603722" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">603722</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">INHIBITOR OF KAPPA LIGHT POLYPEPTIDE GENE ENHANCER IN B CELLS, KINASE COMPLEX-ASSOCIATED PROTEIN; IKBKAP</td></tr></tbody></table></div></div><div id="fd.Molecular_Genetic_Pathogenesis"><h3>Molecular Genetic Pathogenesis</h3><p>The molecular pathogenesis of <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> dysautonomia (FD) was reviewed by <a class="bk_pop" href="#fd.REF.slaugenhaupt.2002.307">Slaugenhaupt &#x00026; Gusella [2002]</a>. In summary, the Elongator complex protein 1 (Elp1) is part of the human Elongator complex, which is thought to be involved in creating a permissive chromatin structure for efficient <a class="def" href="/books/n/gene/glossary/def-item/mrna/">mRNA</a> elongation during transcription. Importantly, despite the presence of a <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> <i>ELP1</i> (<i>IKBKAP</i>) <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, cells from individuals with FD are capable of producing wild type <i>ELP1</i> message and Elp1 protein. The predominant splice donor site variant c.2204+6T&#x0003e;C (formerly IVS20+6T&#x0003e;C) results in variable expression of the <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> in a tissue-specific manner. In individuals with FD the brain expresses primarily mutated <i>ELP1</i> mRNA, whereas lymphoblast and fibroblast cell lines from <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals express primarily wild type <i>ELP1</i> mRNA. Although the molecular basis for this tissue specificity is unknown, it raises the possibility that manipulation of Elp1 protein expression may offer new therapeutic approaches [<a class="bk_pop" href="#fd.REF.ibrahim.2007.41">Ibrahim et al 2007</a>] (see also <a href="#fd.Therapies_Under_Investigation">Therapies Under Investigation</a>).</p><p><b>Gene structure.</b>
<i>ELP1</i> contains 37 exons and encodes a 1332-amino acid protein, Elongator complex protein 1 (Elp1; formerly IKAP) [<a class="bk_pop" href="#fd.REF.anderson.2001.753">Anderson et al 2001</a>, <a class="bk_pop" href="#fd.REF.slaugenhaupt.2001.598">Slaugenhaupt et al 2001</a>]. Northern blot analysis of <i>ELP1</i> reveals two <a class="def" href="/books/n/gene/glossary/def-item/mrna/">mRNA</a> transcripts of 4.8 and 5.9 kb. The transcripts differ only in the length of the 3' untranslated region; they are predicted to encode identical 150-kd proteins. For a detailed summary of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> and protein information, see <a href="/books/NBK1180/#fd.molgen.TA">Table A</a>, <b>Gene</b>.</p><p><b>Pathogenic variants.</b> Only two <i>ELP1</i> pathogenic variants exist in the <a class="def" href="/books/n/gene/glossary/def-item/ashkenazi-jewish/">Ashkenazi Jewish</a> population. The first, c.2204+6T&#x0003e;C, a single T&#x0003e;C change at nucleotide 6 of <a class="def" href="/books/n/gene/glossary/def-item/intron/">intron</a> 20, occurs with an unusually high frequency (&#x0003e;99.5%). The second <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is the <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variant p.Arg696Pro, which is predicted to disrupt a potential phosphorylation site. Indeed, Elp1 carrying the p.Arg696Pro pathogenic variant displays reduced phosphorylation as determined by immunoprecipitation from labeled cells.</p><div id="fd.T.selected_elp1_ikbkap_pathogenic_var" class="table"><h3><span class="label">Table 3. </span></h3><div class="caption"><p>Selected <i>ELP1</i> (<i>IKBKAP</i>) Pathogenic Variants</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1180/table/fd.T.selected_elp1_ikbkap_pathogenic_var/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__fd.T.selected_elp1_ikbkap_pathogenic_var_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_fd.T.selected_elp1_ikbkap_pathogenic_var_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">DNA Nucleotide Change<br />(Alias&#x000a0;<sup>1</sup>)</th><th id="hd_h_fd.T.selected_elp1_ikbkap_pathogenic_var_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Predicted Protein Change</th><th id="hd_h_fd.T.selected_elp1_ikbkap_pathogenic_var_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reference Sequences</th></tr></thead><tbody><tr><td headers="hd_h_fd.T.selected_elp1_ikbkap_pathogenic_var_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.2087G&#x0003e;C</td><td headers="hd_h_fd.T.selected_elp1_ikbkap_pathogenic_var_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Arg696Pro</td><td headers="hd_h_fd.T.selected_elp1_ikbkap_pathogenic_var_1_1_1_3" rowspan="3" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/nuccore/189163479" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_003640<wbr style="display:inline-block"></wbr>​.3</a><br /><a href="/protein/38569394" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_003631<wbr style="display:inline-block"></wbr>​.2</a></td></tr><tr><td headers="hd_h_fd.T.selected_elp1_ikbkap_pathogenic_var_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.2204+6T&#x0003e;C<br />(IVS20+6T&#x0003e;C)</td><td headers="hd_h_fd.T.selected_elp1_ikbkap_pathogenic_var_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">--</td></tr><tr><td headers="hd_h_fd.T.selected_elp1_ikbkap_pathogenic_var_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.2741C&#x0003e;T</td><td headers="hd_h_fd.T.selected_elp1_ikbkap_pathogenic_var_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Pro914Leu</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Note on variant classification: Variants listed in the table have been provided by the authors. <i>GeneReviews</i> staff have not independently verified the classification of variants.</p></div></dd><dt></dt><dd><div><p class="no_margin">Note on nomenclature: <i>GeneReviews</i> follows the standard naming conventions of the Human Genome Variation Society (<a href="http://varnomen.hgvs.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">varnomen<wbr style="display:inline-block"></wbr>​.hgvs.org</a>). See <a href="/books/n/gene/app3/">Quick Reference</a> for an explanation of nomenclature.</p></div></dd><dt>1. </dt><dd><div id="fd.TF.3.1"><p class="no_margin">Variant designation that does not conform to current naming conventions</p></div></dd></dl></div></div></div><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> Elongator complex protein 1 is a 1332-amino acid protein that is homologous to the Elp1 protein of <i>Saccharomyces cerevisiae</i>, a member of the six-subunit Elongator complex associated with hyperphosphorylated RNA polymerase II during transcriptional elongation. One member of the complex, Elp3, is a highly conserved histone acetyltransferase, which suggests that Elongator is involved in creating a chromatin structure that permits efficient elongation of <a class="def" href="/books/n/gene/glossary/def-item/mrna/">mRNA</a> during transcription. Recently, the human Elongator complex was purified and shown to contain Elp1, along with other proteins. Interestingly, although Elp1 was predictably found primarily in the nucleus, it was also detected in the nucleoli and cytoplasm by immunostaining. Moreover, Elp1 could be isolated from cellular fractions that lacked detectable hELP3 (human elongation protein 3), suggesting that perhaps the proteins in the functional Elongator complex have multiple roles in the cell.</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> It was recently shown that the common <a class="def" href="/books/n/gene/glossary/def-item/splicing/">splicing</a> variant c.2204+6T&#x0003e;C is deleterious because it exacerbates the inherently weak splicing nucleotide motifs around <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 20 [<a class="bk_pop" href="#fd.REF.ibrahim.2007.41">Ibrahim et al 2007</a>]. Recent results using <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a>-specific primers demonstrated that every FD cell type examined expressed variable ratios of both wild type and mutated <i>ELP1</i> <a class="def" href="/books/n/gene/glossary/def-item/mrna/">mRNA</a>.</p></div></div><div id="fd.References"><h2 id="_fd_References_">References</h2><div id="fd.Literature_Cited"><h3>Literature Cited</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="fd.REF.acog_committee_on_genetics.2004.425">ACOG Committee on Genetics.  ACOG committee opinion; number 298, August 2004. Prenatal and preconceptional carrier screening for genetic diseases in individuals of Eastern European Jewish descent. <span><span class="ref-journal">Obstet Gynecol. </span>2004;<span class="ref-vol">104</span>:425–8.</span> [<a href="/pubmed/15292027" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15292027</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fd.REF.anderson.2001.753">Anderson SL, Coli R, Daly IW, Kichula EA, Rork MJ, Volpi SA, Ekstein J, Rubin BY. Familial dysautonomia is caused by mutations of the IKAP gene. <span><span class="ref-journal">Am J Hum Genet. </span>2001;<span class="ref-vol">68</span>:753–8.</span> [<a href="/pmc/articles/PMC1274486/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1274486</span></a>] [<a href="/pubmed/11179021" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11179021</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fd.REF.anderson.2012.570">Anderson SL, Liu B, Qiu J, Sturm AJ, Schwartz JA, Peters AJ, Sullivan KA, Rubin BY. Nutraceutical-mediated restoration of wild-type levels of IKBKAP-encoded IKAP protein in familial dysautonomia-derived cells. <span><span class="ref-journal">Mol Nutr Food Res. </span>2012;<span class="ref-vol">56</span>:570–9.</span> [<a href="/pubmed/22495984" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22495984</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fd.REF.anderson.2005.150">Anderson SL, Rubin BY. Tocotrienols reverse IKAP and monoamine oxidase deficiencies in familial dysautonomia. <span><span class="ref-journal">Biochem Biophys Res Commun. </span>2005;<span class="ref-vol">336</span>:150–6.</span> [<a href="/pubmed/16125677" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16125677</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fd.REF.axelrod.1996">Axelrod FB. Familial dysautonomia. In: Robertson D, Low PA, Polinsky RJ, eds. <em>Primer on the Autonomic Nervous System</em>. San Diego, CA: Academic Press; 1996:242-9.</div></li><li class="half_rhythm"><div class="bk_ref" id="fd.REF.axelrod.1999">Axelrod FB. Familial dysautonomia. In: Mathias CJ, Bannister R, eds. <em>Autonomic Failure</em>. 4 ed. Oxford University Press: New York, NY; 1999:402-18.</div></li><li class="half_rhythm"><div class="bk_ref" id="fd.REF.axelrod.2002.i2">Axelrod FB. Hereditary sensory and autonomic neuropathies. Familial dysautonomia and other HSANs. <span><span class="ref-journal">Clin Auton Res. </span>2002;<span class="ref-vol">12</span> Suppl 1:I2–14.</span> [<a href="/pubmed/12102459" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12102459</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fd.REF.axelrod.2009.743">Axelrod FB, Berlin D. Pregabalin: a new approach to treatment of the dysautonomic crisis. <span><span class="ref-journal">Pediatrics. </span>2009;<span class="ref-vol">124</span>:743–6.</span> [<a href="/pubmed/19620195" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19620195</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fd.REF.axelrod.2005.284">Axelrod FB, Goldberg JD, Rolnitzky L, Mull J, Mann SP, Gold von Simson G, Berlin D, Slaugenhaupt SA. Fludrocortisone in patients with familial dysautonomia--assessing effect on clinical parameters and gene expression. <span><span class="ref-journal">Clin Auton Res. </span>2005;<span class="ref-vol">15</span>:284–91.</span> [<a href="/pubmed/16032383" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16032383</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fd.REF.axelrod.2007.39">Axelrod FB, Gold-von Simson G. Hereditary sensory and autonomic neuropathies: types II, III, and IV. <span><span class="ref-journal">Orphanet J Rare Dis. </span>2007;<span class="ref-vol">2</span>:39.</span> [<a href="/pmc/articles/PMC2098750/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2098750</span></a>] [<a href="/pubmed/17915006" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17915006</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fd.REF.axelrod.2011.480">Axelrod FB, Liebes L, Gold-Von Simson G, Mendoza S, Mull J, Leyne M, Norcliffe-Kaufmann L, Kaufmann H, Slaugenhaupt SA. Kinetin improves IKBKAP mRNA splicing in patients with familial dysautonomia. <span><span class="ref-journal">Pediatr Res. </span>2011;<span class="ref-vol">70</span>:480–3.</span> [<a href="/pmc/articles/PMC3189334/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3189334</span></a>] [<a href="/pubmed/21775922" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21775922</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fd.REF.bernardi.2003.141">Bernardi L, Hilz M, Stemper B, Passino C, Welsch G, Axelrod FB. Respiratory and cerebrovascular responses to hypoxia and hypercapnia in familial dysautonomia. <span><span class="ref-journal">Am J Respir Crit Care Med. </span>2003;<span class="ref-vol">167</span>:141–9.</span> [<a href="/pubmed/12406829" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12406829</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fd.REF.blumenfeld.1999.1110">Blumenfeld A, Slaugenhaupt SA, Liebert CB, Temper V, Maayan C, Gill S, Lucente DE, Idelson M, MacCormack K, Monahan MA, Mull J, Leyne M, Mendillo M, Schiripo T, Mishori E, Breakefield X, Axelrod FB, Gusella JF. Precise genetic mapping and haplotype analysis of the familial dysautonomia gene on human chromosome 9q31. <span><span class="ref-journal">Am J Hum Genet. </span>1999;<span class="ref-vol">64</span>:1110–8.</span> [<a href="/pmc/articles/PMC1377835/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1377835</span></a>] [<a href="/pubmed/10090896" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10090896</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fd.REF.bochner.2013.2785">Bochner R, Ziv Y, Zeevi D, Donyo M, Abraham L, Ashery-Padan R, Ast G. Phosphatidylserine increases IKBKAP levels in a humanized knock-in IKBKAP mouse model. <span><span class="ref-journal">Hum Mol Genet. </span>2013;<span class="ref-vol">22</span>:2785–94.</span> [<a href="/pubmed/23515154" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23515154</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fd.REF.brown.2003.163">Brown CM, Stemper B, Welsch G, Brys M, Axelrod FB, Hilz MJ. Orthostatic challenge reveals impaired vascular resistance control, but normal venous pooling and capillary filtration in familial dysautonomia. <span><span class="ref-journal">Clin Sci (Lond). </span>2003;<span class="ref-vol">104</span>:163–9.</span> [<a href="/pubmed/12546638" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12546638</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fd.REF.casella.2005.273">Casella EB, Bousso A, Corvello CM, Fruchtengarten LV, Diament AJ. Episodic somnolence in an infant with Riley-Day syndrome. <span><span class="ref-journal">Pediatr Neurol. </span>2005;<span class="ref-vol">32</span>:273–4.</span> [<a href="/pubmed/15797185" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15797185</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fd.REF.daniel.2014.867">Daniel SJ, Cardona I. Cricothyroid onabotulinum toxin A injection to avert tracheostomy in bilateral vocal fold paralysis. <span><span class="ref-journal">JAMA Otolaryngol Head Neck Surg. </span>2014 Sep;<span class="ref-vol">140</span>(9):867–9.</span> [<a href="/pubmed/25123108" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25123108</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fd.REF.di_rocco.2003.362">Di Rocco M, Stella G, Bruno C, Doria Lamba L, Bado M, Superti-Furga A. Long-term survival in Stuve-Wiedemann syndrome: a neuro-myo-skeletal disorder with manifestations of dysautonomia. <span><span class="ref-journal">Am J Med Genet A. </span>2003;<span class="ref-vol">118A</span>:362–8.</span> [<a href="/pubmed/12687669" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12687669</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fd.REF.dong.2002.253">Dong J, Edelmann L, Bajwa AM, Kornreich R, Desnick RJ. Familial dysautonomia: detection of the IKBKAP IVS20+6T --&#x0003e; C and R696P mutations and frequencies among Ashkenazi Jews. <span><span class="ref-journal">Am J Med Genet. </span>2002;<span class="ref-vol">110</span>:253–7.</span> [<a href="/pubmed/12116234" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12116234</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fd.REF.edvardson.2012.569">Edvardson S, Cinnamon Y, Jalas C, Shaag A, Maayan C, Axelrod FB, Elpeleg O. Hereditary sensory autonomic neuropathy caused by a mutation in dystonin. <span><span class="ref-journal">Ann Neurol. </span>2012;<span class="ref-vol">71</span>:569–72.</span> [<a href="/pubmed/22522446" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22522446</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fd.REF.elkayam.2006.780">Elkayam L, Matalon A, Tseng CH, Axelrod F. Prevalence and severity of renal disease in familial dysautonomia. <span><span class="ref-journal">Am J Kidney Dis. </span>2006;<span class="ref-vol">48</span>:780–6.</span> [<a href="/pubmed/17059997" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17059997</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fd.REF.giarraffa.2005.3377">Giarraffa P, Berger KI, Chaikin AA, Axelrod FB, Davey C, Becker B. Assessing efficacy of high-frequency chest wall oscillation in patients with familial dysautonomia. <span><span class="ref-journal">Chest. </span>2005;<span class="ref-vol">128</span>:3377–81.</span> [<a href="/pubmed/16304287" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16304287</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fd.REF.goldvon_simson.2009.341">Gold-von Simson G, Goldberg JD, Rolnitzky LM, Mull J, Leyne M, Voustianiouk A, Slaugenhaupt SA, Axelrod FB. Kinetin in familial dysautonomia carriers: implications for a new therapeutic strategy targeting mRNA splicing. <span><span class="ref-journal">Pediatr Res. </span>2009;<span class="ref-vol">65</span>:341–6.</span> [<a href="/pubmed/19033881" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19033881</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fd.REF.goldvon_simson.2005.15">Gold-von Simson G, Rutkowski M, Berlin D, Axelrod FB. Pacemakers in patients with familial dysautonomia--a review of experience with 20 patients. <span><span class="ref-journal">Clin Auton Res. </span>2005;<span class="ref-vol">15</span>:15–20.</span> [<a href="/pubmed/15768197" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15768197</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fd.REF.hilz.2002.i33">Hilz MJ. Assessment and evaluation of hereditary sensory and autonomic neuropathies with autonomic and neurophysiological examinations. <span><span class="ref-journal">Clin Auton Res. </span>2002;<span class="ref-vol">12</span> Suppl 1:I33–43.</span> [<a href="/pubmed/12102461" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12102461</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fd.REF.hims.2007.149">Hims MM, Ibrahim EC, Leyne M, Mull J, Liu L, Lazaro C, Shetty RS, Gill S, Gusella JF, Reed R, Slaugenhaupt SA. Therapeutic potential and mechanism of kinetin as a treatment for the human splicing disease familial dysautonomia. <span><span class="ref-journal">J Mol Med. </span>2007;<span class="ref-vol">85</span>:149–61.</span> [<a href="/pubmed/17206408" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17206408</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fd.REF.ibrahim.2007.41">Ibrahim EC, Hims MM, Shomron N, Burge CB, Slaugenhaupt SA, Reed R. Weak definition of IKBKAP exon 20 leads to aberrant splicing in familial dysautonomia. <span><span class="ref-journal">Hum Mutat. </span>2007;<span class="ref-vol">28</span>:41–53.</span> [<a href="/pubmed/16964593" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16964593</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fd.REF.keren.2010.e15884">Keren H, Donyo M, Zeevi D, Maayan C, Pupko T, Ast G. Phosphatidylserine increases IKBKAP levels in familial dysautonomia cells. <span><span class="ref-journal">PLoS One. </span>2010;<span class="ref-vol">5</span>:e15884.</span> [<a href="/pmc/articles/PMC3012102/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3012102</span></a>] [<a href="/pubmed/21209961" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21209961</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fd.REF.lee.2009.402">Lee G, Papapetrou EP, Kim H, Chambers SM, Tomishima MJ, Fasano CA, Ganat YM, Menon J, Shimizu F, Viale A, Tabar V, Sadelain M, Studer L. Modelling pathogenesis and treatment of familial dysautonomia using patient specific iPSCs. <span><span class="ref-journal">Nature. </span>2009;<span class="ref-vol">461</span>:402–6.</span> [<a href="/pmc/articles/PMC2784695/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2784695</span></a>] [<a href="/pubmed/19693009" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19693009</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fd.REF.lee.2012.1244">Lee G, Ramirez CN, Kim H, Zeltner N, Liu B, Radu C, Bhinder B, Kim YJ, Choi IY, Mukherjee-Clavin B, Djaballah H, Studer L. Large-scale screening using familial dysautonomia induced pluripotent stem cells identifies compounds that rescue IKBKAP expression. <span><span class="ref-journal">Nat Biotechnol. </span>2012;<span class="ref-vol">30</span>:1244–8.</span> [<a href="/pmc/articles/PMC3711177/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3711177</span></a>] [<a href="/pubmed/23159879" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23159879</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fd.REF.lehavi.2003.139">Lehavi O, Aizenstein O, Bercovich D, Pavzner D, Shomrat R, Orr-Urtreger A, Yaron Y. Screening for familial dysautonomia in Israel: evidence for higher carrier rate among Polish Ashkenazi Jews. <span><span class="ref-journal">Genet Test. </span>2003;<span class="ref-vol">7</span>:139–42.</span> [<a href="/pubmed/12885336" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12885336</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fd.REF.leyne.2003.305">Leyne M, Mull J, Gill SP, Cuajungco MP, Oddoux C, Blumenfeld A, Maayan C, Gusella JF, Axelrod FB, Slaugenhaupt SA. Identification of the first non-Jewish mutation in familial dysautonomia. <span><span class="ref-journal">Am J Med Genet A. </span>2003;<span class="ref-vol">118A</span>:305–8.</span> [<a href="/pubmed/12687659" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12687659</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fd.REF.liu.2013.3632">Liu B, Anderson SL, Qiu J, Rubin BY. Cardiac glycosides correct aberrant splicing of IKBKAP-encoded mRNA in familial dysautonomia derived cells by suppressing expression of SRSF3. <span><span class="ref-journal">FEBS J. </span>2013;<span class="ref-vol">280</span>:3632–46.</span> [<a href="/pubmed/23711097" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23711097</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fd.REF.marthol.2003.912">Marthol H, Tutaj M, Brys M, Brown CM, Hecht MJ, Berlin D, Axelrod FB, Hilz MJ. Clonidine improves postprandial baroreflex control in familial dysautonomia. <span><span class="ref-journal">Eur J Clin Invest. </span>2003;<span class="ref-vol">33</span>:912–8.</span> [<a href="/pubmed/14511364" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14511364</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fd.REF.maayan.2000.679">Maayan C, Sela O, Axelrod F, Kidron D, Hochner-Celnikier D. Gynecological aspects of female familial dysautonomia. <span><span class="ref-journal">Isr Med Assoc J. </span>2000;<span class="ref-vol">2</span>:679–83.</span> [<a href="/pubmed/11062768" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11062768</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fd.REF.norcliffekaufmann.2013.1611">Norcliffe-Kaufmann L, Martinez J, Axelrod F, Kaufmann H. Hyperdopaminergic crises in familial dysautonomia: a randomized trial of carbidopa. <span><span class="ref-journal">Neurology. </span>2013;<span class="ref-vol">80</span>:1611–7.</span> [<a href="/pmc/articles/PMC3662326/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3662326</span></a>] [<a href="/pubmed/23553478" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23553478</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fd.REF.palma.2014.2653">Palma JA, Norcliffe-Kaufmann L, Fuente-Mora C, Percival L, Mendoza-Santiesteban C, Kaufmann H. Current treatments in familial dysautonomia. <span><span class="ref-journal">Expert Opin Pharmacother. </span>2014;<span class="ref-vol">15</span>:2653–71.</span> [<a href="/pmc/articles/PMC4236240/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4236240</span></a>] [<a href="/pubmed/25323828" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25323828</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fd.REF.rubin.2008.837">Rubin BY, Anderson SL, Kap&#x000e1;s L. Can the therapeutic efficiency of tocotrienols in neurodegenerative familial dysautonomia patients be measured clinically? <span><span class="ref-journal">Antioxid Redox Signal. </span>2008;<span class="ref-vol">10</span>:837–41.</span> [<a href="/pubmed/18177231" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18177231</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fd.REF.saini.2003.209">Saini J, Axelrod FB, Maayan C, Stringer J, Smilen SW. Urinary incontinence in familial dysautonomia. <span><span class="ref-journal">Int Urogynecol J Pelvic Floor Dysfunct. </span>2003;<span class="ref-vol">14</span>:209–13.</span> [<a href="/pubmed/12955345" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12955345</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fd.REF.sands.2006.457">Sands SA, Giarraffa P, Jacobson CM, Axelrod FB. Familial dysautonomia's impact on quality of life in childhood, adolescence, and adulthood. <span><span class="ref-journal">Acta Paediatr. </span>2006;<span class="ref-vol">95</span>:457–62.</span> [<a href="/pubmed/16720494" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16720494</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fd.REF.slaugenhaupt.2004.429">Slaugenhaupt SA, Mull J, Leyne M, Cuajungco MP, Gill SP, Hims MM, Quintero F, Axelrod FB, Gusella JF. Rescue of a human mRNA splicing defect by the plant cytokinin kinetin. <span><span class="ref-journal">Hum Mol Genet. </span>2004;<span class="ref-vol">13</span>:429–36.</span> [<a href="/pubmed/14709595" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14709595</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fd.REF.slaugenhaupt.2001.598">Slaugenhaupt SA, Blumenfeld A, Gill SP, Leyne M, Mull J, Cuajungco MP, Liebert CB, Chadwick B, Idelson M, Reznik L, Robbins C, Makalowska I, Brownstein M, Krappmann D, Scheidereit C, Maayan C, Axelrod FB, Gusella JF. Tissue-specific expression of a splicing mutation in the IKBKAP gene causes familial dysautonomia. <span><span class="ref-journal">Am J Hum Genet. </span>2001;<span class="ref-vol">68</span>:598–605.</span> [<a href="/pmc/articles/PMC1274473/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1274473</span></a>] [<a href="/pubmed/11179008" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11179008</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fd.REF.slaugenhaupt.2002.307">Slaugenhaupt SA, Gusella JF. Familial dysautonomia. <span><span class="ref-journal">Curr Opin Genet Dev. </span>2002;<span class="ref-vol">12</span>:307–11.</span> [<a href="/pubmed/12076674" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12076674</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fd.REF.tutaj.2006.65">Tutaj M, Marthol H, Berlin D, Brown CM, Axelrod FB, Hilz MJ. Effect of physical countermaneuvers on orthostatic hypotension in familial dysautonomia. <span><span class="ref-journal">J Neurol. </span>2006;<span class="ref-vol">253</span>:65–72.</span> [<a href="/pubmed/16096819" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16096819</span></a>]</div></li></ul></div></div><div id="fd.Chapter_Notes"><h2 id="_fd_Chapter_Notes_">Chapter Notes</h2><div id="fd.Author_History"><h3>Author History</h3><p>Gabrielle J Halpern, MB, ChB; Beilinson Hospital, Petah Tikva (1999-2014)<br />Mordechai Shohat, MD (1999-present)<br />Monika Weisz Hubshman, MD, PhD (2014-present)</p></div><div id="fd.Revision_History"><h3>Revision History</h3><ul><li class="half_rhythm"><div>18 December 2014 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>1 June 2010 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>22 October 2007 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>10 January 2005 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>21 January 2003 (me) Review posted live</div></li><li class="half_rhythm"><div>6 November 1999 (bp) Original submission</div></li></ul></div></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © 1993-2019, University of Washington, Seattle. GeneReviews is
a registered trademark of the University of Washington, Seattle. All rights
reserved.<p class="small">GeneReviews® chapters are owned by the University of Washington. Permission is
hereby granted to reproduce, distribute, and translate copies of content materials for
noncommercial research purposes only, provided that (i) credit for source (<a href="http://www.genereviews.org/" ref="pagearea=meta&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">http://www.genereviews.org/</a>) and copyright (© 1993-2019 University of
Washington) are included with each copy; (ii) a link to the original material is provided
whenever the material is published elsewhere on the Web; and (iii) reproducers,
distributors, and/or translators comply with the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>. No further modifications are allowed. For clarity, excerpts
of GeneReviews chapters for use in lab reports and clinic notes are a permitted
use.</p><p class="small">For more information, see the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>.</p><p class="small">For questions regarding permissions or whether a specified use is allowed,
contact: <a href="mailto:dev@null" data-email="ude.wu@tssamda" class="oemail">ude.wu@tssamda</a>.</p></div><div class="small"><span class="label">Bookshelf ID: NBK1180</span><span class="label">PMID: <a href="/pubmed/20301359" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">20301359</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/factor-v-leiden/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/fevr/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK1180&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK1180/?report=reader">PubReader</a></li><li><a href="/books/NBK1180/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK1180" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK1180" style="display:none" title="Cite this Page"><div class="bk_tt">Shohat M, Weisz Hubshman M. Familial Dysautonomia. 2003 Jan 21 [Updated 2014 Dec 18]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. <span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK1180/pdf/Bookshelf_NBK1180.pdf">PDF version of this page</a> (223K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>In this GeneReview</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="page-toc" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="#fd.Summary" ref="log$=inpage&amp;link_id=inpage">Summary</a></li><li><a href="#fd.Diagnosis" ref="log$=inpage&amp;link_id=inpage">Diagnosis</a></li><li><a href="#fd.Clinical_Characteristics" ref="log$=inpage&amp;link_id=inpage">Clinical Characteristics</a></li><li><a href="#fd.Genetically_Related_Allelic_Disorders" ref="log$=inpage&amp;link_id=inpage">Genetically Related (Allelic) Disorders</a></li><li><a href="#fd.Differential_Diagnosis" ref="log$=inpage&amp;link_id=inpage">Differential Diagnosis</a></li><li><a href="#fd.Management" ref="log$=inpage&amp;link_id=inpage">Management</a></li><li><a href="#fd.Genetic_Counseling" ref="log$=inpage&amp;link_id=inpage">Genetic Counseling</a></li><li><a href="#fd.Resources" ref="log$=inpage&amp;link_id=inpage">Resources</a></li><li><a href="#fd.Molecular_Genetics" ref="log$=inpage&amp;link_id=inpage">Molecular Genetics</a></li><li><a href="#fd.References" ref="log$=inpage&amp;link_id=inpage">References</a></li><li><a href="#fd.Chapter_Notes" ref="log$=inpage&amp;link_id=inpage">Chapter Notes</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>GeneReviews Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/gene/advanced/"><i>GeneReviews</i> Advanced Search</a></li><li><a href="/books/n/gene/glossary/"><i>GeneReviews</i> Glossary</a></li><li><a href="/books/n/gene/resource_mats/">Resource Materials</a> <span class="bk_hlight1">NEW FEATURE</span></li><li><a href="/books/n/gene/updates/">New in <i>GeneReviews</i></a></li><li><a href="/books/n/gene/authors/">Author List</a></li><li><a href="/books/n/gene/prospective_authors/">For Current/Prospective Authors</a></li><li><a href="/books/n/gene/GRpersonnel/"><i>GeneReviews</i> Personnel</a></li><li><a href="/books/n/gene/howto_linkin/">Download/Link to <i>GeneReviews</i></a></li><li><a href="/books/n/gene/contact_us/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Tests in GTR by Gene</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=8518[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">ELP1</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=omim&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_omim&amp;IdsFromResult=1471210" ref="log$=recordlinks">OMIM</a><div class="brieflinkpop offscreen_noflow">Related OMIM records</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=1471210" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=1471210" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=gene&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_gene&amp;IdsFromResult=1471210" ref="log$=recordlinks">Gene</a><div class="brieflinkpop offscreen_noflow">Locus Links</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301726" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Congenital Insensitivity to Pain with Anhidrosis</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Congenital Insensitivity to Pain with Anhidrosis<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Indo Y. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/28667575" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Animal and cellular models of familial dysautonomia.</a><span class="source">[Clin Auton Res. 2017]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Animal and cellular models of familial dysautonomia.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Lefcort F, Mergy M, Ohlen SB, Ueki Y, George L. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Clin Auton Res. 2017 Aug; 27(4):235-243. Epub 2017 Jun 30.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301468" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Congenital Muscular Dystrophy Overview</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Congenital Muscular Dystrophy Overview<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Sparks SE, Quijano-Roy S, Harper A, Rutkowski A, Gordon E, Hoffman EP, Pegoraro E. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/28167615" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedarticles&amp;logdbfrom=pubmed">The familial dysautonomia disease gene &lt;i&gt;IKBKAP&lt;/i&gt; is required in the developing and adult mouse central nervous system.</a><span class="source">[Dis Model Mech. 2017]</span><div class="brieflinkpop offscreen_noflow">The familial dysautonomia disease gene &lt;i&gt;IKBKAP&lt;/i&gt; is required in the developing and adult mouse central nervous system.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Chaverra M, George L, Mergy M, Waller H, Kujawa K, Murnion C, Sharples E, Thorne J, Podgajny N, Grindeland A, et al. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Dis Model Mech. 2017 May 1; 10(5):605-618. Epub 2017 Feb 6.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/12116234" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Familial dysautonomia: detection of the IKBKAP IVS20(+6T --&amp;gt; C) and R696P mutations and frequencies among Ashkenazi Jews.</a><span class="source">[Am J Med Genet. 2002]</span><div class="brieflinkpop offscreen_noflow">Familial dysautonomia: detection of the IKBKAP IVS20(+6T --&amp;gt; C) and R696P mutations and frequencies among Ashkenazi Jews.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Dong J, Edelmann L, Bajwa AM, Kornreich R, Desnick RJ. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Am J Med Genet. 2002 Jul 1; 110(3):253-7. </em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=20301359" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=20301359" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=5e041acadd21425a2572d1e8">Familial Dysautonomia - GeneReviews®</a><div class="ralinkpop offscreen_noflow">Familial Dysautonomia - GeneReviews®<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2019-12-25T21:28:26-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@5.22&amp;Host=portal101&amp;ncbi_phid=CE880F07E04166610000000001FB00C7&amp;ncbi_session=CE880F07E041ACA1_0507SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK1180%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK1180&amp;ncbi_domain=gene&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK1180/&amp;ncbi_pagename=Familial Dysautonomia - GeneReviews® - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE880F07E041ACA1_0507SID /projects/books/PBooks@5.22 portal101 v4.1.r585844 Mon, May 06 2019 02:53:16 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>